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ABSTRACT  1 
Purpose. Leptin is associated with cardiovascular risk factors (e.g. hypertension, insulin resistance, kidney disease and 2 
excess body weight). Experimental studies showed that leptin might affect serum uric acid, by modulation of the uric 3 
acid excretion. However, there are few observational data on the relationship between leptin and uric acid in general 4 
population. Therefore, the aim of the present study was to evaluate the relationship between leptin and uric acid and its 5 
excretion in a large middle-aged male general population. 6 
Methods. A sample of 930 adult male individuals (mean age: 52 years) without therapy for high uric acid was included 7 
in the analysis (the Olivetti Heart Study).  8 
Results. Uric acid was significantly and positively associated with blood pressure, BMI, waist circumference, insulin 9 
resistance, C-reactive protein and leptin (p<0.01), while inversely with renal function (p=0.01). The multivariate 10 
analysis confirmed the association between leptin and uric acid after adjustment for potential confounders (p<0.01). 11 
After division for adiposity, this trend was confirmed separately for normal weight and excess body weight participants. 12 
Moreover, leptin was inversely associated with excretion of uric acid (p<0.01), also in multivariate analysis (p=0.03). 13 
Conclusion. The results of this study indicate a positive association between circulating leptin levels and uric acid, 14 
independently of potential confounders, both in normal and excess body weight men.  Furthermore, an inverse 15 

















Leptin (LPT) is a protein hormone mainly produced by adipose tissue [1]. LPT exerts different effects, in 2 
particular it is implicated in the regulation of body weight modulating appetite, energy expenditure and satiety, but it is 3 
also involved in the regulation of inflammation [1,2]. High circulating LPT levels are common in excess body weight 4 
individuals, the higher the BMI or the waist circumference (WC), the higher the LPT level [1,3], suggesting a LPT 5 
resistance. 6 
 However, our previous data suggested that LPT was positively associated with increased cardiovascular risk 7 
independently of body weight, increasing the development of hypertension [4], metabolic syndrome [5], insulin 8 
resistance [6] and declining renal function [7].  9 
 Serum uric acid (SUA), major product of the purine metabolism, is catabolized by xanthine oxidase and 10 
predominantly eliminated by the kidney. Although some studies indicated contrasting data on SUA oxidant effects [8,9], 11 
clinical studies suggested a positive and strong association between SUA and cardio-metabolic risk factors (e.g. obesity, 12 
insulin resistance, hypertension and metabolic syndrome [8,10,11,12], or early and overt cardiovascular organ damage 13 
[8]. In addition, genetic studies detected variants in SUA reabsorption and excretion transporters that are involved in 14 
this regulation [13] both in general population [14] and in patients at high cardiovascular risk [15]. In this context, the 15 
balance between overproduction and excretion of SUA may play a key role in determining SUA plasma levels [13].  16 
The role of LPT on SUA is supported by experimental data that pointed out the effect on modulation of SUA excretion. 17 
High LPT stimulates the sympathetic nervous system (SNS) independently of body weight, and this increased 18 
sympathetic activity mainly at kidney level may led to stimulate renin release and to increase proximal sodium 19 
reabsorption [16], that in turn is positively associated with reabsorption of SUA [17]. The effect of LPT could be also 20 
mediated by the strong positive relationship with insulin levels and insulin resistance [3,6], that are positively associated 21 
with SUA [18]. Indeed, also insulin may increase proximal sodium reabsorption though an activation of sodium-22 
hydrogen exchange in proximal renal tubular cells, that in turn promotes a parallel increase in urate reabsorption [17]. 23 
As expected, this increased activity is also associated with insulin resistance [19].  On the other hand, since more than 24 
90% of filtered urate is reabsorbed by the kidney, renal damage could affect this complex process, and in this context 25 
LPT may play a crucial role. Indeed, LPT may unfavourably contribute to the decline in renal function [7] both by a 26 
direct effect of nephron disruption and by an indirect effect though an inflammation status and a higher insulin 27 
resistance [20,21]. High LPT is involved in the promotion and progression of endothelial dysfunction and vascular 28 
damage, in particular it exerts the effects through glomerular endothelial cell proliferation, increased synthesis of 29 
collagen and hypertrophy of the mesangium cells [20,21], increased serum levels of adhesion molecules [20] and 30 
contributing to vascular remodelling [22]. However, so far there are few observational studies aimed to evaluate the 31 
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association between LPT and SUA. In particular, LPT was positively associated with SUA in a large sample of Japanese 1 
women [23], as well as in a small sample of diabetic [24] or obese men [25] or middle-aged adult men [26], while in 2 
healthy [27] or non-obese male subjects [25] there was not relationship. These conflicting results may be due to the 3 
heterogeneity in size and features of the samples and to the covariates included in the multivariate models. 4 
 In consideration of this premise, the primary aim of the present study was to evaluate the relationship between 5 
LPT and SUA in a large middle-aged male general population participating in the Olivetti Heart Study (OHS). 6 




MATERIALS AND METHODS 11 
Study Population 12 
The OHS was an occupational investigation of the male workforce of the Olivetti factories in Southern Italy, as 13 
previously described [28,29]. From a total of 1085 individuals aged 25–75 years examined in 1994-95, 930 participants 14 
without therapy for high SUA and with variables available for this study were included in the present analysis. The 15 
Ethics Committee of “Federico II” University in Naples approved the Olivetti study protocol and the participants 16 
provided their informed written consent to participate. 17 
 18 
Examination Procedures 19 
The OHS study procedures have been previously described [28,29]. Briefly, the participants were allowed to pursue 20 
their normal activities, but they were discouraged from engaging in vigorous exercise. They were asked to abstain from 21 
smoking and drinking alcohol, coffee, tea and other beverages containing caffeine starting on the night before the visit. 22 
The visit included a physical examination and anthropometric measurements, a blood test, a fasting timed urine 23 
collection and the administration of a detailed questionnaire on demographic and medical information. Body weight, 24 
height, WC and systolic/diastolic blood pressure (BP) were measured as previously described [28,29]. The diagnosis of 25 
hypertension was defined as systolic BP > 140 and/or diastolic BP >90 mmHg or current antihypertensive drug 26 
treatment [30]. Body mass index (BMI) was measured according to the formula weight [kg]/height2.  Excess body 27 
weight was defined as a BMI ≥ 25 kg/m2. Central obesity was given by a WC value ≥ 102 cm. A fasting venous blood 28 
sample was taken in the seated position to obtain the determination of metabolic parameters. Blood specimens were 29 
immediately centrifuged and stored at -70 °C until analysis (Cobas-Mira; Roche, Milan, Italy). Serum LPT was 30 
measured by an enzyme-linked immunosorbent assay (R&D System GmbH, Wiesbaden-Nordenstadt, Germany) [31]. 31 
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Creatinine in serum was measured by the picric acid colorimetric method and in urine samples by atomic absorption 1 
spectrophotometry, and was used to estimate the renal creatinine clearance (CrCl), expressed as: mL/min/1.73 m2. 2 
Serum insulin concentration was measured by radioimmunoassay (Insulina Lisophase; Technogenetics, Milan, Italy). 3 
Insulin sensitivity was estimated by the homeostasis model assessment (Homa) using the formula: fasting plasma 4 
insulin (μU/mL) x fasting plasma glucose (mmol/L)/22.5. High-Sensitivity C-Reactive Protein (CRP) was assessed by 5 
an immunoturbidimetric method (Roche Diagnostics, Milan, Italy, automated analyser).  6 
The protocol for the assessment of the timed urine collection was previously reported [32]. Volume and length of 7 
urinary collections were recorded and specimens were examined for electrolytes, creatinine, SUA and lithium 8 
determinations. Standard formulas were used to calculate the clearances of creatinine, sodium, lithium, and SUA. Data 9 
were then expressed as fractional excretion (FE) by dividing the respective clearance by the CrCl and were expressed as 10 
percentages (%). 11 
 12 
Statistical analysis  13 
All statistical analyses were performed using the SPSS software, version 23 (SPSS inc, Chicago,Ill). Because the 14 
distribution of LPT, SUA, CRP and Homa were skewed, the log-transformed values were used in the analyses. Bivariate 15 
relationships between the variables under investigation were evaluated by Pearson correlation analysis. Moreover, the 16 
participants were also stratified according to the tertiles of the sample LPT distribution and by body weight. The 17 
analysis of variance (ANOVA) was used to assess differences in main features among LPT tertiles and unpaired t-test to 18 
assess differences between normal weight and excess body weight participants. The multivariate linear regression 19 
analysis was used to determine the relationship between continuous variables, adjusting for the main potential 20 
confounders. Given the strong relationship between BMI and WC (r=0.81, p<0.001) in this sample, multivariate 21 
analyses were separately adjusted for BMI or WC.  The results are reported as mean or geometric mean (with standard 22 
deviation – SD) or percentages, unless otherwise indicated. A post-hoc evaluation detected a power of 90% (alpha error: 23 
5%) to detect in this sample a true difference of 0.64 mg/dl (SD= 1.2) in SUA between the highest and the lowest tertile 24 
of LPT. Two-sided P values below 0.05 were considered statistically significant.  25 
 26 
RESULTS 27 
The relevant characteristics of the study participants are reported in Table 1. The mean age was 52.0 (7.5) years, with 28 
74% having excess body weight, 18% central obesity, 42% hypertension, 7% diabetes, and 15% high SUA (more than 29 
7.0 mg/dl). The analysis of the comparison between SUA levels and the most relevant characteristics of the participants 30 
showed a significant and positive association with LPT (r=0.19, p<0.001), BP (systolic: r=0.14, p<0.001; diastolic: 31 
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r=0.19, p<0.001), BMI (r=0.26, p<0.001), WC (r=0.24, p<0.001),  Homa (r=0.12, p<0.001) and CRP (r=0.14, p<0.001), 1 
inversely with CrCl (r=-0.09, p=0.01), while no association was found with age (p=0.5). The multivariate analysis 2 
confirmed the association between LPT and SUA, after accounting for age, BP, therapy, CrCl, Homa and CRP (Table 2). 3 
Separate analyses adjusted also for BMI or WC found a significant trend between LPT and SUA (p<0.05) (Table 2). 4 
Likewise, also after exclusion of participants with high SUA, LPT was significantly associated with SUA (for 1-SD 5 
increase in log-LPT, β= 0.10, 0.03 to 0.18, p<0.01). In addition, the relationship between LPT and SUA was explored in 6 
normal and excess body weight participants, separately. The individuals with excess body weight had higher WC, BP, 7 
BP, CRP, Homa, SUA and LPT than normal weight participants (p<0.01) (Table 3). Also after this stratification, a 8 
significant and positive association between LPT and SUA was detected in both normal and excess body weight 9 
participants (for 1-SD increase in log-LPT (2.4 ng/mL): normal weight, β= 0.18, 0.03 to 0.33, p=0.02; excess body 10 
weight, β= 0.10, 0.02 to 0.18, p=0.01). Finally, the analysis on urinary excretions showed that FE of uric acid was 11 
inversely associated with LPT (r= -0.11, p=0.001), in addition to the expected association with SUA (r= -0.46, 12 
p<0.001). The association between LPT and FE of uric acid was confirmed after adjusting for age, BMI and therapy (for 13 
1-SD increase in log-LPT: β= -0.29, -0.57 to -0.02, p=0.03).  14 
We also stratified the group as a whole by tertiles of LPT: highest tertile of LPT had significantly higher SUA and age, 15 
and as expected greater BP, BMI, WC, Homa and CRP than lower tertiles (Figure 1 and Table 4). Conversely, the 16 
groups did not differ for CrCl (Table 3). The multivariate analysis confirmed the significant positive association 17 
between LPT tertiles and SUA also accounting for potential confounders such as age, BP, BMI (or WC), CrCl, Homa, 18 
CRP and therapy (p for trend=0.01). Moreover, FE of uric acid decreased through LPT tertiles form the lowest to the 19 





Our results are in line with our previous studies indicating a strong relationship between LPT, BP, anthropometric 25 
indices, insulin sensitivity and PCR [3-7].  In addition to our knowledge, this is the first study, in a relatively large 26 
general adult population of men without treatment for high SUA, indicating that LPT levels are associated positively 27 
with SUA and inversely with FE of uric acid, after accounting for potential confounders, such as age, BP, insulin 28 
sensitivity, renal function, inflammation marker, therapy and anthropometric measures. In addition, this relationship was 29 




Previous epidemiological studies indicated that high SUA level is a risk factor for cardiovascular disease [11,33,34] and 1 
it is strongly and positively associated with high BP, obesity, insulin resistance and metabolic syndrome [8,34,35,36]. 2 
High levels of SUA could be determined by dysregulation and imbalance between overproduction and renal excretion. 3 
In addition, also genetics may be involved in this regulation, probably by genetic polymorphisms of GLUT9 urate 4 
transporter gene that was associated with SUA and urinary urate excretion in our general population [14] and with 5 
cardiovascular risk factors in patients at high risk [15].  6 
At our knowledge few observational data were available on the association between LPT and SUA: in a large sample of 7 
Japanese women, LPT was independently associated with SUA after adjusting for main confounders [23]. Although in 8 
agreement with our results, these findings cannot be compared with ours because of the well-known differences in LPT 9 
and SUA levels between men and women. The significant association between LPT and SUA was also found in a small 10 
sample of obese diabetic and non-diabetic male and female participants [24]. However, this association was not 11 
accounted for any expression of insulin sensitivity. A similar limitation may be pointed out for an analysis including a 12 
small sample of healthy middle-aged adults, in which LPT was positively associated with SUA only in men [26]. 13 
Another positive correlation between LPT and SUA was also found in a sample of 200 men, but it was significant only 14 
in overweight and obese participants, after adjusting for potential confounders [25]. Conversely, in a small sample of 15 
healthy men there was no association between LPT levels and SUA [27]. These conflicting results in male populations 16 
may be due to the small sample size and to the heterogeneity of the participants’ characteristics.  17 
As a matter of a fact, experimental data suggest that LPT may play  a role  on the  regulation  of the SUA excretion [37] 18 
by modulation of renal sodium handling, by activation of SNS [16,17] and alteration of insulin sensitivity 19 
[3,6,17,18,19,38], and on the other hand by damage at glomerular site [20]. Of note, in our sample LPT levels were 20 
positively associated with proximal fractional sodium reabsorption (data not show) (independent predictor of 21 
hypertension in the same population [39]), and that in turn was also inversely associated with FE of uric acid (data not 22 
show). This finding is supported by the detection of an inverse relationship between SUA excretion and lithium 23 
excretion (data not show), as well as found in previous study [40].         24 
Several studies found a direct relationship between LPT, inflammation and SUA [41,42,43,44].. Our data confirmed the 25 
positive association between LPT and CRP, as well as reported in previous analysis [7]. However, the role of LPT on 26 
SUA did not change after inclusion of this covariate in the analysis.  27 
Some classes of drugs may affect both LPT and SUA levels. LPT is reduced by the administration of antidiabetic 28 
therapy [45,46,47,48,49] or statins [50]. While, SUA may be affected by antihypertensive drugs [51]. Anyhow, in 29 
consideration of this evidence the models were adjusted for these covariates, hence the results were independent by 30 
drugs use.  31 
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In previous epidemiological studies, LPT was higher than in our sample [24,25,27], while SUA was greater in obese 1 
diabetic and non-diabetic participants [24], similar in a small general population sample [25], while lower in healthy 2 
subjects [27]. This difference may be due to the large homogeneous unselected sample included in our analysis in 3 
respect to the selected and small samples of other studies. Important of note is that although LPT resistance is 4 
essentially present in obese or overweight individuals, our results show that LPT is associated with SUA in normal 5 
weight subjects; in addition, SUA increased towards to higher tertiles of LPT.  6 
In the absence of a threshold for the LPT resistance, the results substantially confirm the threshold detected in our 7 
previous study [6] suggesting that for a 2.4 ng/mL LPT increase there was a significant change in SUA levels, 8 
independently of body weight.  9 
The strengths of our study are: the relatively large general population of men, the careful standardization of data 10 
collection, the comprehensive covariates included in the models (i.e. age, BP, antihypertensive-hypolipidemic-11 
antidiabetic therapy, BMI, WC, Homa, CRP and CrCl), and the large availability of urinary determinations. 12 
Nevertheless, the study has some limitations: the first one is the cross-sectional design. However, this limitation is 13 
overcome by evaluation of potential mechanisms involved. The second potential limitation is the participation of only 14 
adult white men, which makes our results only generalizable to male Caucasian people. Third, the circulating leptin-15 
receptor and the serum LPT interacting proteins were not evaluated.  16 
 17 
CONCLUSIONS 18 
The present analysis of a non-selected sample of adult male population drawn from the Olivetti Heart Study 19 
database, indicated that LPT levels are positively associated with SUA, independently of the main potential 20 
confounders, in particular body weight, BP, insulin sensitivity, therapy, inflammation and renal function. In addition, 21 
this relationship is supported by the independent association between LPT and FE of uric acid, in turn supported by 22 
its interaction with proximal fractional sodium reabsorption. The results of this investigation are in line with our 23 
previous studies on the relationship between LPT and cardio-metabolic and cardiovascular risk. Hence, different 24 
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Legend to Figure  1 
 2 
Figure 1. Serum uric acid (SUA) and fractional excretion (FE) of uric acid stratified by tertiles of leptin (LPT). The 3 
analysis of variance (ANOVA) was used to assess the differences in SUA and its FE among LPT tertiles. Data expressed 4 
as mean and standard error.  SUA is expressed as geometric mean.  5 






























Table 1. Baseline characteristics of the study participants. 3 
 4 
N. of participants 930 
Age (yrs) 52.0 (7.5) 
BMI (kg/m2) 26.9 (3.0) 
Waist Circumference (cm) 94.7 (8.3) 
Systolic BP (mmHg) 130.2 (17.3) 
Diastolic BP (mmHg) 84.2 (10.0) 
HOMA index (U)‡ 2.0 (1.8) 
C-Reactive Protein (mg/L)‡ 1.2 (2.5) 
Uric Acid (mg/dL)‡ 5.6 (1.3) 
LPT (ng/mL)‡ 2.7 (2.4) 
Creatinine Clearance (mL/min*1.73 m2) 84.7 (28.2) 
Therapy (%)  
Antihypertensive drugs  17 
Hypolipidaemic drugs 13 
Antidiabetic drugs 3 
















Table 2. Association between uric acid and leptin levels by linear regression analysis. 3 
 4 
 
Increase in UA (1-SD log-UA*) 
β (95% CI) 
P-value 
1-SD ↑ in log-Leptin*   
Unadjusted  0.19 (0.13 to 0.26) <0.001 
Multivariable Model a 0.14 (0.08 to 0.21) <0.001 
Multivariable Model b 0.08 (0.01 to 0.15) 0.038 
Multivariable Model c 0.08 (0.01 to 0.16) 0.02 
UA: uric acid; *1-SD log-Leptin=2.4 ng/mL, 1-SD log-UA= 1.3 mg/dL. 5 
a Adjusted for age, creatinine clearance, systolic blood pressure, antihypertensive-hypolipidemic-antidiabetic treatment, 6 
Homa, CRP.  7 
b Adjusted for Model a plus BMI. 8 


















Table 3. Characteristics of the participants stratified by body weight (n=930). 1 
 2 
 Normal weight Excess body weight 
N. of participants 242 688 
Age (yrs) 52.0 (7.8) 52.0 (7.5) 
BMI (kg/m2) 23.3 (1.4) 28.2 (2.3)* 
Waist Circumference (cm) 86.7 (5.8) 97.6 (7.1)* 
Systolic BP (mmHg) 126.0 (15.9) 131.7 (17.4)* 
Diastolic BP (mmHg) 80.8 (9.2) 85.3 (9.9)* 
C-Reactive Protein (mg/L)‡ 0.95 (2.75) 1.32 (2.51)†* 
HOMA index (U)‡  1.55 (1.66) 2.23 (1.73)†* 
Creatinine Clearance (mL/min*1.73 m2) 82.4 (26.1) 85.6 (28.9) 
Uric Acid (mg/dL)‡ 5.2 (1.3) 5.7 (1.2) †* 
LPT (ng/mL)‡ 1.62 (2.29) 3.23 (2.3)†* 
Data are expressed as means (SD); BP: Blood Pressure. The unpaired t-test was used to assess differences in main 3 
features between normal weight and excess body weight participants.  ‡ Data expressed as geometric mean; † analysis 4 


















Table 4. Characteristics of the participants stratified by tertiles of leptin (n=930). 2 
 3 
 I  tertile II tertile III tertile 
N. of participants 307 310 313 
Age (yrs) 51.9 (7.5) 51.2 (7.1) 53.0 (7.8)* 
BMI (kg/m2) 25.2 (2.8) 26.7 (2.3) 28.8 (2.9)* 
Waist Circumference (cm) 90.0 (7.6) 94.0 (6.7) 100.0 (7.4)* 
Systolic BP (mmHg) 128.0 (18.0) 128.0 (16.4) 134.7 (16.7)* 
Diastolic BP (mmHg) 81.9 (10.4) 83.7 (9.2) 87.9 (9.6)* 
C-Reactive Protein (mg/L)‡ 1.07 (2.75) 1.10 (2.63) 1.55 (2.34)†* 
HOMA index (U)‡  1.70 (1.74) 2.04 (1.70) 2.45 (1.74)†* 
Creatinine Clearance (mL/min*1.73 m2) 84.1 (26.9) 85.6 (29.6) 84.5 (28.2) 
LPT (ng/mL)‡ 0.98 (2.04) 5.49 (1.20) 6.46 (1.48)†* 
Data are expressed as means (SD); BP: Blood Pressure. The analysis of variance (ANOVA) was used to assess 4 
differences in main features among LPT tertiles. ‡ Data expressed as geometric mean;  † analysis performed on log-5 
transformed variable; * p<0.01. 6 
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